
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is projected to continue its strong revenue growth, driven by its innovative products and expanding market opportunities. The company's focus on diversification and securing Medicare coverage positions them well for future success. With a solid track record of beating expectations, Natera has the potential for considerable growth in the coming years.
Bears say
Natera is a company with strong growth potential, driven by its innovative and market-leading products in NIPT, carrier screening, and minimal residual disease testing for cancer. However, there are concerns surrounding its high R&D expenses and the possibility of not meeting investor expectations for revenue growth in its Signatera MRD unit, which could negatively impact the stock. Additionally, while the company has raised its 2026 revenue guidance, it is still operating at a loss and has a history of negative earnings per share.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares